MX2011005430A - Metodo para el tratamiento de la enfermedad de parkinson usando bacetriofago filamentoso. - Google Patents

Metodo para el tratamiento de la enfermedad de parkinson usando bacetriofago filamentoso.

Info

Publication number
MX2011005430A
MX2011005430A MX2011005430A MX2011005430A MX2011005430A MX 2011005430 A MX2011005430 A MX 2011005430A MX 2011005430 A MX2011005430 A MX 2011005430A MX 2011005430 A MX2011005430 A MX 2011005430A MX 2011005430 A MX2011005430 A MX 2011005430A
Authority
MX
Mexico
Prior art keywords
bacteriophage
antibody
filamentous
synuclein
pro
Prior art date
Application number
MX2011005430A
Other languages
English (en)
Spanish (es)
Inventor
Beka Solomon
Haim M Diment
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of MX2011005430A publication Critical patent/MX2011005430A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2011005430A 2008-11-24 2009-11-24 Metodo para el tratamiento de la enfermedad de parkinson usando bacetriofago filamentoso. MX2011005430A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11744608P 2008-11-24 2008-11-24
PCT/US2009/065659 WO2010060073A2 (en) 2008-11-24 2009-11-24 Method for treating parkinson's disease

Publications (1)

Publication Number Publication Date
MX2011005430A true MX2011005430A (es) 2011-10-28

Family

ID=41572327

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011005430A MX2011005430A (es) 2008-11-24 2009-11-24 Metodo para el tratamiento de la enfermedad de parkinson usando bacetriofago filamentoso.

Country Status (17)

Country Link
US (1) US20110286970A1 (ja)
EP (2) EP2478911A1 (ja)
JP (1) JP2012509672A (ja)
KR (1) KR20110091778A (ja)
CN (1) CN102223887B (ja)
AU (1) AU2009316326A1 (ja)
BR (1) BRPI0921557A2 (ja)
CA (1) CA2744339A1 (ja)
CO (1) CO6390112A2 (ja)
HK (1) HK1162964A1 (ja)
IL (1) IL213120A0 (ja)
MX (1) MX2011005430A (ja)
NZ (1) NZ592928A (ja)
RU (1) RU2011125971A (ja)
SG (1) SG171791A1 (ja)
WO (1) WO2010060073A2 (ja)
ZA (1) ZA201104701B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555128T1 (de) 2006-11-30 2012-05-15 Res Dev Foundation Verbesserte immunglobulin-bibliotheken
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque
CA2829223A1 (en) 2011-03-11 2012-09-20 Beka Solomon Method for treating neurodegenerative tauopathy
WO2013016644A1 (en) 2011-07-27 2013-01-31 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
AU2012346056B2 (en) 2011-11-29 2018-02-22 Proclara Biosciences, Inc. Use of P3 of bacteriophage as amyloid binding agents
WO2014055515A1 (en) 2012-10-02 2014-04-10 Neurophage Pharmaceuticals, Inc. Use of p3 of bacteriophage fusion proteins as amyloid binding agents
JP2016526044A (ja) 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ， インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド
TW201632542A (zh) 2014-12-03 2016-09-16 神經噬菌體製藥股份有限公司 包含缺乏醣基化信號之修飾噬菌體ｇ３ｐ胺基酸序列的多肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018169A2 (en) * 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases
EP1335937A2 (en) * 2000-11-24 2003-08-20 Isis Innovation Limited Mixed fibrils
WO2003076455A2 (en) * 2002-03-05 2003-09-18 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
AU2006211625A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
DK1853285T3 (da) * 2005-02-01 2011-06-27 Univ Ramot Fremgangsmåde til behandling af inflammation forbundet med amyloidaflejringer og hjerneinflammation som involverer aktiverede mikroglia
WO2007095616A2 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
CA2659032A1 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque

Also Published As

Publication number Publication date
IL213120A0 (en) 2011-07-31
EP2478911A1 (en) 2012-07-25
HK1162964A1 (en) 2012-09-07
NZ592928A (en) 2012-12-21
SG171791A1 (en) 2011-07-28
CA2744339A1 (en) 2010-05-27
CO6390112A2 (es) 2012-02-29
KR20110091778A (ko) 2011-08-12
CN102223887A (zh) 2011-10-19
US20110286970A1 (en) 2011-11-24
EP2358377A2 (en) 2011-08-24
BRPI0921557A2 (pt) 2019-09-24
JP2012509672A (ja) 2012-04-26
ZA201104701B (en) 2012-09-26
AU2009316326A1 (en) 2010-05-27
CN102223887B (zh) 2013-11-06
WO2010060073A2 (en) 2010-05-27
WO2010060073A3 (en) 2010-09-02
RU2011125971A (ru) 2012-12-27

Similar Documents

Publication Publication Date Title
MX2011005430A (es) Metodo para el tratamiento de la enfermedad de parkinson usando bacetriofago filamentoso.
Caruso Bavisotto et al. Extracellular vesicle-mediated cell–cell communication in the nervous system: Focus on neurological diseases
EP2054515B1 (en) Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
Aguzzi et al. The transcellular spread of cytosolic amyloids, prions, and prionoids
Zheng et al. Plasma exosomes spread and cluster around β-amyloid plaques in an animal model of Alzheimer’s disease
Volpicelli-Daley et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death
US8980547B2 (en) Method for treating neurodegenerative tauopathy
US20110182948A1 (en) Method for treating disease characterized by plaque
Spencer et al. Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders
JP2008528688A (ja) アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法
JP2009529320A (ja) 脳への送達のための抗体および免疫複合体のバインダーとしてのプロテインａをディスプレイする繊維状バクテリオファージ
Zhang et al. Brain targeting and Aβ binding bifunctional nanoparticles inhibit amyloid protein aggregation in APP/PS1 transgenic mice
Huang et al. Microglial-Targeted nSMase2 Inhibitor Fails to Reduce Tau Propagation in PS19 Mice
Ross The Development of Antibody Loaded Liposomes for the Treatment of Alzheimer's Disease
Fernandez Bonfante Discovery and characterisation of anti-amyloid beta fibril antibodies from naive phage display VHH libraries
Elsherbini CERAMIDE-ENRICHED EXTRACELLULAR VESICLES: A ROLE IN ENHANCING AMYLOID-BETA NEUROTOXICITY AND MITOCHONDRIAL DAMAGE IN ALZHEIMER’S DISEASE
Peres Role for Lipids in the Cellular Transmission of α-Synuclein
Cox Nanoparticles for Therapy and Diagnosis of Neurodegenerative Diseases
Silva Engineering of specific bacteriophages for early diagnosis of Alzheimer's disease
Resende Validation of a bacteriophage platform for early detection of Alzheimer’s disease
Solomon Bacteriophage Therapies Targets Multiple Diseases Caused by Protein Misfolding
Solomon In Vivo Targeting of Amyloid Plaques Via Intranasal Administration of Phage Anti-β-Amyloid Antibodies
Armstrong Targeting α-Synuclein Pathology Spread Using an α-Synuclein-specific Nanobody
Ravvin The Biochemical Foundations of Alzheimer’s Disease and Potential for Immune Therapies
Schmidt The immunomodulatory effects of Interferon ß in the ApdE9 transgenic mouse model: a potential therapeutic strategy against Alzheimer's disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal